— Fundamental Stock Analysis and Report Card
Located in Summit, NJ, US. Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q1 2026 Total ($) | Q1 2026 Margin (%) | |
|---|---|---|
| Revenue | 3.9b +168.0m +4.5% | |
| Gross Income | 2.3b +134.0m +6.2% | 59% +0.9pp +1.6% |
| EBITDA | 910.0m +209.0m +29.8% | 23% +4.5pp +24.2% |
| Operating Income | 855.0m +297.0m +53.2% | 22% +7.0pp +46.6% |
| Net Income | 474.0m +152.0m +47.2% | 12% +3.5pp +40.9% |
| Earnings Per Share | 0.25 +0.1 +47.1% | |
| Operating Cash Flow | 489.0m +61.0m +14.3% | 13% +1.1pp +9.3% |
| Free Cash Flow | 350.0m +101.0m +40.6% | 9% +2.3pp +34.5% |
| Research & Development | 84.0m +84.0m n/a | 2% +2.1pp n/a |